Headquartered in South County Business Park, Dublin Fiscal year ends December NASDAQ: ICLR iconplc.com
ICON plc is an Irish-incorporated company operating in the diagnostics and research sector within healthcare. The company provides contract research organization (CRO) services, supporting pharmaceutical, biotechnology, and medical device companies in the clinical development of new drugs and therapies. ICON's shares are represented by American Depositary Shares traded in the United States. The company maintains a global workforce of employees and engages consultants and non-executive directors, for whom it operates equity incentive plans to attract and retain talent and align interests with shareholders. Updated
A 1.56x net book-to-bill lifted backlog 4.8% sequentially to $24.5 billion, rebuilding the revenue pipeline even as the top line slipped year over year. Management also raised the buyback authorization to $750 million.
Pre-Market Stock Futures: Futures are trading higher this morning, after all the big funds and portfolio managers may have shown their hands on Wednesday, as the tech and chip stocks sell-off resumed…
Citi swept through its life science tools and diagnostics coverage on Wednesday, opening a 90-day upside catalyst watch on Agilent Technologies (NYSE:A | A Price Prediction) while trimming its price target on…
The relentless bull run led by high-flying growth stocks is no longer here, and 2025 has brought a significant shift in the market landscape, with the S&P 500 now in correction territory.…
ICON plc is an Irish-incorporated company operating in the diagnostics and research sector within healthcare. The company provides contract research organization (CRO) services, supporting pharmaceutical, biotechnology, and medical device companies in the clinical development of new drugs and therapies.
24/7 Wall St.'s 12-month price target for ICLR is $219.98, rated Hold. The Wall Street consensus target is $188.24. ICLR price prediction →
